EDS-FLU performs differently than other nasal corticosteroids

We appreciate the commentary by Fokkens and Reitsma1 and respectfully wish to draw attention to several issues raised by the discussion. A  Cochrane analysis of previous inhaled nasal corticosteroid (INCS) studies was used as the basis for comparison with phase 3 data for the exhalation delivery system with fluticasone (EDS-FLU).2-4 However, this meta-analysis included a combination of data for “conventional” nasal sprays, nasal d rops, and a phase 2 study with an earlier version of the EDS-FLU.3,4 Given the expectation that effects of locally acting drugs can vary substantially based on the location of deposition and clear evidence that the site of deposition with an EDS is different than with conventional nasal sprays,5-7 i t is important to recognize that these meta-analysis results identified marked differences in response between conventional and EDS delivery.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Correspondence Source Type: research